CH
MTNB icon

CVI Holdings’s Matinas BioPharma MTNB Stock Holding History

CVI Holdings’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,193
Closed -$991K – 73
2019
Q1 		$991K Buy
+18,193
New +$980K 0.94% 17

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

CVI Holdings's MTNB Position: Q2 2019 in Review

CVI Holdings sold out of Matinas BioPharma (MTNB) in Q2 2019, closing a stake of 18,193 shares — an estimated $991K sold.

CVI Holdings first reported a position in MTNB in Q1 2019 and held it in 1 quarter. The position peaked at $991K in Q1 2019. 47 funds tracked by Wall St. Rank hold MTNB as of Q2 2019.

  • CVI Holdings reported no remaining Matinas BioPharma position as of Q2 2019 after selling out during the quarter.
  • CVI Holdings sold 18,193 Matinas BioPharma shares in Q2 2019, an estimated $991K.
  • CVI Holdings first reported a position in Matinas BioPharma in Q1 2019 and held it in 1 quarter.
  • CVI Holdings's Matinas BioPharma position peaked at $991K in Q1 2019.
  • 47 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2019.

Based on CVI Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.